Dr Reddy’s Laboratories launches generic version of vasopressin injection in US

Dr Reddy’s Laboratories yesterday announced the launch of its authorised generic version of Par Pharmaceutical’s Vasostrict (vasopressin injection, USP) vials in the US market approved by the US Food and Drug Administration (FDA), a company statement notified.

Dr Reddy’s vasopressin injection, USP, is supplied in a carton of 25 single-dose vials each containing
vasopressin 1 mL at 20 units/mL, it further stated.

The vasostrict brand market had US sales of approximately $878.5 million MAT for the most recent twelve months ending in December 2021, according to IQVIA Health, concluded the statement.